Loss of Efficacy of Pasireotide After its Re-Administration: is There a Reason Why?

por Mandanas, Stylianos, Mathiopoulou, Lemonia, Boudina, Maria, Chrisoulidou, Alexandra, Pazaitou-Panayiotou, Kalliopi
Publicado 2016

Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer

por Chrisoulidou, Alexandra, Mandanas, Stylianos, Margaritidou, Efterpi, Mathiopoulou, Lemonia, Boudina, Maria, Georgopoulos, Konstantinos, Pazaitou-Panayiotou, Kalliopi
Publicado 2015

Parathyroid involvement in thyroid cancer: an unforeseen event

por Chrisoulidou, Alexandra, Mandanas, Stylianos, Mitsakis, Periklis, Iliadou, Paschalia K, Manafis, Kosmas, Flaris, Nikolaos, Boudina, Maria, Mathiopoulou, Lemonia, Pazaitou-Panayiotou, Kalliopi
Publicado 2012